CrossBridge Bio
Address: Texas Medical Center Innovation 2450, Holcombe Blvd., Suite X, Houston, TX 77021About Us
CrossBridge Bio is a biotechnology company focused on developing innovative dual-payload ADC therapeutics.
Sectors
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Manufacture
- Collaborations & Partnerships-Services
- Contract Research & Development
- Proprietary Research & Manufacture
- Drug Delivery
Categories
- Biologics
- Drug Delivery Technology
- Drug Development Services
- Clinical Development-Pipeline
- Tumour Targeting
- Antibody Drug Conjugates
- Drug Conjugates & Linkers
- ADC-Payload
- Bioconjugation
News
CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly
HOUSTON--(BUSINESS WIRE)--CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) today announced a definitive agreement to be acquired by Eli Lilly and Company (“Lilly”).
CrossBridge Bio, a Houston-based biotechnology firm founded in 2023, is developing a new dual-payload ADC technology originally created by Kyoji Tsuchikama at the University of Texas Health Science Center at Houston (UTHealth Houston). The company is focused on advancing next-generation ADCs with the potential to transform clinical practice. Its lead candidate, CBB-120, is a TROP2-targeting TOP1i/ATRi dual-payload ADC for cancer treatment. It is designed to enhance the therapeutic index and generate more durable responses compared to current TROP2-targeting ADCs, while also addressing key resistance mechanisms. U.S. Food and Drug Administration Investigational New Drug application for CBB-120 is anticipated in 2026.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com